This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 115/11/1417    most recent CIRCULATIONAHA.106.631549v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Magne, J. Articles by Pibarot, P. Search for Related Content PubMed PubMed Citation Articles by Magne, J. Articles by Pibarot, P. Related Collections Valvular heart disease CV surgery: valvular disease

(Circulation. 2007;115:1417-1425.)
© 2007 American Heart Association, Inc.

Valvular Heart Disease

Impact of Prosthesis-Patient Mismatch on Survival After Mitral Valve Replacement

Julien Magne, MSc; Patrick Mathieu, MD, FRCPC; Jean G. Dumesnil, MD, FRCPC; David Tanné, Eng; François Dagenais, MD, FRCPC; Daniel Doyle, MD, FRCPC; Philippe Pibarot, DVM, PhD

From the Laval Hospital Research Center/Québec Heart Institute, Faculty of Medicine, Laval University, Québec, Canada (J.M., P.M., J.G.D., D.T., F.D., D.D., P.P.), and Cardiovascular Biomechanics Team (IRPHE-CNRS), Université de la Méditerranée, Marseilles, France (D.T.).

Correspondence to Dr Philippe Pibarot, Laval Hospital Research Center, 2725 Chemin Sainte-Foy, Sainte-Foy, Quebec, Canada, G1V-4G5. E-mail philippe.pibarot{at}med.ulaval.ca

Received April 7, 2006; accepted December 21, 2006.

Background— We recently reported that valve prosthesis-patient mismatch (PPM) is associated with persisting pulmonary hypertension after mitral valve replacement. Thus, the objective of this study was to evaluate the impact of PPM on mortality in patients undergoing mitral valve replacement.

Methods and Results— The indexed valve effective orifice area was estimated for each type and size of prosthesis being implanted in 929 consecutive patients and used to define PPM as not clinically significant if >1.2 cm²/m², as moderate if >0.9 and 1.2 cm²/m², and as severe if 0.9 cm²/m². Moderate PPM was present in 69% of patients; severe PPM was seen in 9%. For patients with severe PPM, 6-year survival (74±5%) and 12-year survival (63±7%) were significantly less than for patients with moderate PPM (84±1% and 76±2%; P=0.027) or nonsignificant PPM (90±2% and 82±4%; P=0.002). On multivariate analysis, severe PPM was associated with higher mortality (hazard ratio, 3.2; 95% confidence interval, 1.5 to 6.8; P=0.003).

Conclusions— Severe PPM is an independent predictor of mortality after mitral valve replacement. As opposed to other independent risk factors, PPM may be avoided or its severity may be reduced with the use of a prospective strategy at the time of operation. For patients identified as being at risk for severe PPM, every effort should be made to implant a prosthesis with a larger effective orifice area.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				J. Magne, M. Senechal, P. Mathieu, J. G. Dumesnil, F. Dagenais, and P. Pibarot Restrictive Annuloplasty for Ischemic Mitral Regurgitation May Induce Functional Mitral Stenosis J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1692 - 1701. [Abstract] [Full Text] [PDF]

				S. H. Rahimtoola The Year in Valvular Heart Disease. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 760 - 770. [Full Text] [PDF]

				P. Totaro and V. Argano Reply to the Editor. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 465 - 466. [Full Text] [PDF]

				P. Pibarot, J. Magne, and J. G. Dumesnil Prosthesis-patient mismatch after mitral valve replacement: back to reality. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 464 - 465. [Full Text] [PDF]

				R. M. Bolman III Survival After Mitral Valve Replacement: Does the Valve Type and/or Size Make a Difference? Circulation, March 20, 2007; 115(11): 1336 - 1338. [Full Text] [PDF]